{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T23:40:46Z","timestamp":1794699646396,"version":"4.9.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>BRAF<\/jats:italic>\n                    genomic alterations are the most common oncogenic drivers in pediatric low-grade glioma (pLGG). Arm 1 (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200977) of the ongoing phase 2 FIREFLY-1 (PNOC026) trial investigated the efficacy of the oral, selective, central nervous system\u2013penetrant, type II RAF inhibitor tovorafenib (420\u2009mg\u2009m\n                    <jats:sup>\u2212<\/jats:sup>\n                    <jats:sup>2<\/jats:sup>\n                    once weekly; 600\u2009mg maximum) in patients with\n                    <jats:italic>BRAF<\/jats:italic>\n                    -altered, relapsed\/refractory pLGG. Arm 2 (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200960) is an extension cohort, which provided treatment access for patients with\n                    <jats:italic>RAF<\/jats:italic>\n                    -altered pLGG after arm 1 closure. Based on independent review, according to Response Assessment in Neuro-Oncology High-Grade Glioma (RANO-HGG) criteria, the overall response rate (ORR) of 67% met the arm 1 prespecified primary endpoint; median duration of response (DOR) was 16.6\u2009months; and median time to response (TTR) was 3.0\u2009months (secondary endpoints). Other select arm 1 secondary endpoints included ORR, DOR and TTR as assessed by Response Assessment in Pediatric Neuro-Oncology Low-Grade Glioma (RAPNO) criteria and safety (assessed in all treated patients and the primary endpoint for arm 2,\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009137). The ORR according to RAPNO criteria (including minor responses) was 51%; median DOR was 13.8\u2009months; and median TTR was 5.3\u2009months. The most common treatment-related adverse events (TRAEs) were hair color changes (76%), elevated creatine phosphokinase (56%) and anemia (49%). Grade \u22653 TRAEs occurred in 42% of patients. Nine (7%) patients had TRAEs leading to discontinuation of tovorafenib. These data indicate that tovorafenib could be an effective therapy for\n                    <jats:italic>BRAF<\/jats:italic>\n                    -altered, relapsed\/refractory pLGG. ClinicalTrials.gov registration:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04775485?term=NCT04775485&amp;rank=1\" ext-link-type=\"uri\">NCT04775485<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s41591-023-02668-y","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T08:01:51Z","timestamp":1700208111000},"page":"207-217","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":213,"title":["The type II RAF inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1478-3619","authenticated-orcid":false,"given":"Lindsay B.","family":"Kilburn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6305-7790","authenticated-orcid":false,"given":"Dong-Anh","family":"Khuong-Quang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7733-383X","authenticated-orcid":false,"given":"Jordan R.","family":"Hansford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Landi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8186-338X","authenticated-orcid":false,"given":"Jasper","family":"van der Lugt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0225-6184","authenticated-orcid":false,"given":"Sarah E. S.","family":"Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3135-3872","authenticated-orcid":false,"given":"Pablo Hern\u00e1iz","family":"Driever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4763-4329","authenticated-orcid":false,"given":"Simon","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Perreault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"McCowage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela J.","family":"Waanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7451-7916","authenticated-orcid":false,"given":"David S.","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Witt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia A.","family":"Baxter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1009-6002","authenticated-orcid":false,"given":"Hyoung Jin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy E.","family":"Hassall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8936-1205","authenticated-orcid":false,"given":"Jung Woo","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8219-9807","authenticated-orcid":false,"given":"Darren","family":"Hargrave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5361-7683","authenticated-orcid":false,"given":"Andrea T.","family":"Franson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Yalon Oren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Toledano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4082-7267","authenticated-orcid":false,"given":"Val\u00e9rie","family":"Larouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7765-7690","authenticated-orcid":false,"given":"Cassie","family":"Kline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed S.","family":"Abdelbaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2485-3692","authenticated-orcid":false,"given":"Nada","family":"Jabado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1082-6776","authenticated-orcid":false,"given":"Nicholas G.","family":"Gottardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1783-631X","authenticated-orcid":false,"given":"Nicolas U.","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas S.","family":"Whipple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9740-1286","authenticated-orcid":false,"given":"Devorah","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan N.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liat","family":"Oren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica E. K.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-9357","authenticated-orcid":false,"given":"Sabine","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izzy","family":"Cornelio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"McLeod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Da Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Manley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel C.","family":"Blackman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger J.","family":"Packer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2935-0058","authenticated-orcid":false,"given":"Karsten","family":"Nysom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,17]]},"reference":[{"key":"2668_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40478-020-00902-z","volume":"8","author":"S Ryall","year":"2020","unstructured":"Ryall, S., Tabori, U. & Hawkins, C. Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathol. Commun. 8, 30 (2020).","journal-title":"Acta Neuropathol. Commun."},{"key":"2668_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1055\/a-0889-8256","volume":"231","author":"AK Gnekow","year":"2019","unstructured":"Gnekow, A. K. et al. SIOP-E-BTG and GPOH guidelines for diagnosis and treatment of children and adolescents with low grade glioma. Klin. Padiatr. 231, 107\u2013135 (2019).","journal-title":"Klin. Padiatr."},{"key":"2668_CR3","doi-asserted-by":"publisher","first-page":"e2300017","DOI":"10.1200\/GO.23.00017","volume":"9","author":"DC Moreira","year":"2023","unstructured":"Moreira, D. C. et al. Tackling pediatric low-grade gliomas: a global perspective. JCO Glob. Oncol. 9, e2300017 (2023).","journal-title":"JCO Glob. Oncol."},{"key":"2668_CR4","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1200\/JCO.2011.36.6054","volume":"30","author":"JL Ater","year":"2012","unstructured":"Ater, J. L. et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children\u2019s Oncology Group. J. Clin. Oncol. 30, 2641\u20132647 (2012).","journal-title":"J. Clin. Oncol."},{"key":"2668_CR5","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s11060-018-03048-0","volume":"141","author":"AM Heitzer","year":"2019","unstructured":"Heitzer, A. M. et al. Neuropsychological outcomes of patients with low-grade glioma diagnosed during the first year of life. J. Neurooncol. 141, 413\u2013420 (2019).","journal-title":"J. Neurooncol."},{"key":"2668_CR6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/neuonc\/nox141","volume":"20","author":"DTW Jones","year":"2018","unstructured":"Jones, D. T. W. et al. Pediatric low-grade gliomas: next biologically driven steps. Neuro Oncol. 20, 160\u2013173 (2018).","journal-title":"Neuro Oncol."},{"key":"2668_CR7","doi-asserted-by":"publisher","first-page":"a011254","DOI":"10.1101\/cshperspect.a011254","volume":"4","author":"DK Morrison","year":"2012","unstructured":"Morrison, D. K. MAP kinase pathways. Cold Spring Harb. Perspect. Biol. 4, a011254 (2012).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2668_CR8","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1634\/theoncologist.2017-0242","volume":"22","author":"A Johnson","year":"2017","unstructured":"Johnson, A. et al. Comprehensive genomic profiling of 282 pediatric low- and high-grade gliomas reveals genomic drivers, tumor mutational burden, and hypermutation signatures. Oncologist 22, 1478\u20131490 (2017).","journal-title":"Oncologist"},{"key":"2668_CR9","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.ccell.2020.03.011","volume":"37","author":"S Ryall","year":"2020","unstructured":"Ryall, S. et al. Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas. Cancer Cell 37, 569\u2013583 (2020).","journal-title":"Cancer Cell"},{"key":"2668_CR10","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3390\/cancers11060794","volume":"11","author":"F Behling","year":"2019","unstructured":"Behling, F. & Schittenhelm, J. Oncogenic BRAF alterations and their role in brain tumors. Cancers (Basel) 11, 794 (2019).","journal-title":"Cancers (Basel)"},{"key":"2668_CR11","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s00401-015-1410-7","volume":"129","author":"VP Collins","year":"2015","unstructured":"Collins, V. P., Jones, D. T. & Giannini, C. Pilocytic astrocytoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 129, 775\u2013788 (2015).","journal-title":"Acta Neuropathol."},{"key":"2668_CR12","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1097\/NEN.0000000000000226","volume":"74","author":"C Faulkner","year":"2015","unstructured":"Faulkner, C. et al. BRAF fusion analysis in pilocytic astrocytomas: KIAA1549-BRAF 15-9 fusions are more frequent in the midline than within the cerebellum. J. Neuropathol. Exp. Neurol. 74, 867\u2013872 (2015).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"2668_CR13","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","volume":"389","author":"E Bouffet","year":"2023","unstructured":"Bouffet, E. et al. Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations. N. Engl. J. Med. 389, 1108\u20131120 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2668_CR14","unstructured":"Dabrafenib prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/202806s025lbl.pdf"},{"key":"2668_CR15","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1200\/JCO.22.01000","volume":"41","author":"E Bouffet","year":"2023","unstructured":"Bouffet, E. et al. Efficacy and safety of trametinib monotherapy or in combination with dabrafenib in pediatric BRAFV600-mutant low-grade glioma. J. Clin. Oncol. 41, 664\u2013674 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2668_CR16","doi-asserted-by":"publisher","first-page":"7303","DOI":"10.1158\/1078-0432.CCR-19-2177","volume":"25","author":"DR Hargrave","year":"2019","unstructured":"Hargrave, D. R. et al. Efficacy and safety of dabrafenib in pediatric patients with BRAF V600 mutation-positive relapsed or refractory low-grade glioma: results from a phase I\/IIa study. Clin. Cancer Res. 25, 7303\u20137311 (2019).","journal-title":"Clin. Cancer Res."},{"key":"2668_CR17","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1158\/2159-8290.CD-18-1321","volume":"9","author":"R Yaeger","year":"2019","unstructured":"Yaeger, R. & Corcoran, R. B. Targeting alterations in the RAF-MEK pathway. Cancer Discov. 9, 329\u2013341 (2019).","journal-title":"Cancer Discov."},{"key":"2668_CR18","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.celrep.2019.09.009","volume":"29","author":"T Botton","year":"2019","unstructured":"Botton, T. et al. Genetic heterogeneity of BRAF fusion kinases in melanoma affects drug responses. Cell Rep. 29, 573\u2013588 e577 (2019).","journal-title":"Cell Rep."},{"key":"2668_CR19","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1093\/neuonc\/nou059","volume":"16","author":"MA Karajannis","year":"2014","unstructured":"Karajannis, M. A. et al. Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. Neuro Oncol. 16, 1408\u20131416 (2014).","journal-title":"Neuro Oncol."},{"key":"2668_CR20","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","volume":"20","author":"J Fangusaro","year":"2019","unstructured":"Fangusaro, J. et al. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol. 20, 1011\u20131022 (2019).","journal-title":"Lancet Oncol."},{"key":"2668_CR21","doi-asserted-by":"publisher","first-page":"vi59","DOI":"10.1093\/neuonc\/noab196.231","volume":"23","author":"S Perreault","year":"2021","unstructured":"Perreault, S. et al. A phase 2 study of trametinib for patients with pediatric glioma with activation of the MAPK\/ERK pathway. Neuro Oncol. 23, vi59\u2013vi60 (2021).","journal-title":"Neuro Oncol."},{"key":"2668_CR22","doi-asserted-by":"publisher","first-page":"i191","DOI":"10.1093\/neuonc\/noac079.716","volume":"24","author":"N Robison","year":"2022","unstructured":"Robison, N. et al. MEK162 (binimetinib) in children with progressive or recurrent low-grade glioma: a multi-institutional phase II and target validation study. Neuro Oncol. 24, i191\u2013i192 (2022).","journal-title":"Neuro Oncol."},{"key":"2668_CR23","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s11523-022-00888-9","volume":"17","author":"T Trippett","year":"2022","unstructured":"Trippett, T. et al. Cobimetinib in pediatric and young adult patients with relapsed or refractory solid tumors (iMATRIX-cobi): a multicenter, phase I\/II study. Target. Oncol. 17, 283\u2013293 (2022).","journal-title":"Target. Oncol."},{"key":"2668_CR24","doi-asserted-by":"publisher","first-page":"100857","DOI":"10.1016\/j.neo.2022.100857","volume":"36","author":"N Manoharan","year":"2023","unstructured":"Manoharan, N., Liu, K. X., Mueller, S., Haas-Kogan, D. A. & Bandopadhayay, P. Pediatric low-grade glioma: targeted therapeutics and clinical trials in the molecular era. Neoplasia 36, 100857 (2023).","journal-title":"Neoplasia"},{"key":"2668_CR25","first-page":"774","volume":"19","author":"Y Sun","year":"2017","unstructured":"Sun, Y. et al. A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. Neuro Oncol. 19, 774\u2013785 (2017).","journal-title":"Neuro Oncol."},{"key":"2668_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00280-023-04544-5","volume":"92","author":"DW Rasco","year":"2023","unstructured":"Rasco, D. W. et al. Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma. Cancer Chemother. Pharmacol. 92, 15\u201328 (2023).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2668_CR27","unstructured":"Lee, J. et al. Clinical activity of the type II pan-RAF inhibitor tovorafenib in BRAF-fusion melanoma. Poster 174 presented at the 19th European Association of Dermato-Oncology Congress. https:\/\/publications.dayonebio.com\/Clinical+activity+of+the+type+II+pan-RAF+inhibitor+tovorafenib+in+BRAF-fusion+melanoma.pdf (2023)."},{"key":"2668_CR28","doi-asserted-by":"publisher","first-page":"e2300065","DOI":"10.1200\/PO.23.00065","volume":"7","author":"K Offer","year":"2023","unstructured":"Offer, K. et al. Activity of type II RAF inhibitor tovorafenib in a pediatric patient with a recurrent spindle cell sarcoma harboring a novel SNX8\u2013BRAF gene fusion. JCO Precis. Oncol. 7, e2300065 (2023).","journal-title":"JCO Precis. Oncol."},{"key":"2668_CR29","doi-asserted-by":"crossref","unstructured":"Wright, K. et al. PNOC014: phase IB study results of DAY101(tovorafenib) for children with low-grade gliomas (LGGs) and other RAS\/RAF\/MEK\/ERK pathway-activated tumors. Neuro Oncol. 24, vii84 (2022).","DOI":"10.1093\/neuonc\/noac209.318"},{"key":"2668_CR30","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","volume":"28","author":"PY Wen","year":"2010","unstructured":"Wen, P. Y. et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J. Clin. Oncol. 28, 1963\u20131972 (2010).","journal-title":"J. Clin. Oncol."},{"key":"2668_CR31","doi-asserted-by":"publisher","first-page":"e305","DOI":"10.1016\/S1470-2045(20)30064-4","volume":"21","author":"J Fangusaro","year":"2020","unstructured":"Fangusaro, J. et al. Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol. 21, e305\u2013e316 (2020).","journal-title":"Lancet Oncol."},{"key":"2668_CR32","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1200\/JCO.2017.72.7511","volume":"35","author":"PY Wen","year":"2017","unstructured":"Wen, P. Y. et al. Response Assessment in Neuro-Oncology clinical trials. J. Clin. Oncol. 35, 2439\u20132449 (2017).","journal-title":"J. Clin. Oncol."},{"key":"2668_CR33","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1200\/JCO.2011.34.5843","volume":"30","author":"E Bouffet","year":"2012","unstructured":"Bouffet, E. et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J. Clin. Oncol. 30, 1358\u20131363 (2012).","journal-title":"J. Clin. Oncol."},{"key":"2668_CR34","doi-asserted-by":"crossref","unstructured":"Kilburn, L. et al. Clinical activity of pan-RAF inhibitor tovorafenib in the registrational pediatric low-grade glioma arm of the phase 2 FIREFLY-1 (PNOC026) study. J. Clin. Oncol. 41, 10004 (2023).","DOI":"10.1200\/JCO.2023.41.16_suppl.10004"},{"key":"2668_CR35","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1093\/neuonc\/noab047","volume":"23","author":"J Fangusaro","year":"2021","unstructured":"Fangusaro, J. et al. A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study. Neuro Oncol. 23, 1777\u20131788 (2021).","journal-title":"Neuro Oncol."},{"key":"2668_CR36","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1093\/neuonc\/now282","volume":"19","author":"A Banerjee","year":"2017","unstructured":"Banerjee, A. et al. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro Oncol. 19, 1135\u20131144 (2017).","journal-title":"Neuro Oncol."},{"key":"2668_CR37","first-page":"1546","volume":"9","author":"Y Ma","year":"2019","unstructured":"Ma, Y., Wang, Q., Dong, Q., Zhan, L. & Zhang, J. How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy. Am. J. Cancer Res. 9, 1546\u20131553 (2019).","journal-title":"Am. J. Cancer Res."},{"key":"2668_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-023-00580-9","volume":"23","author":"S Monch","year":"2023","unstructured":"Monch, S. et al. Patterns of pseudoprogression across different cancer entities treated with immune checkpoint inhibitors. Cancer Imaging 23, 58 (2023).","journal-title":"Cancer Imaging"},{"key":"2668_CR39","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/annonc\/mdz003","volume":"30","author":"E Borcoman","year":"2019","unstructured":"Borcoman, E. et al. Novel patterns of response under immunotherapy. Ann. Oncol. 30, 385\u2013396 (2019).","journal-title":"Ann. Oncol."},{"key":"2668_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11493-2","volume":"10","author":"ZJ Reitman","year":"2019","unstructured":"Reitman, Z. J. et al. Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells. Nat. Commun. 10, 3731 (2019).","journal-title":"Nat. Commun."},{"key":"2668_CR41","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s11060-020-03640-3","volume":"149","author":"F Selt","year":"2020","unstructured":"Selt, F. et al. Response to trametinib treatment in progressive pediatric low-grade glioma patients. J. Neurooncol. 149, 499\u2013510 (2020).","journal-title":"J. Neurooncol."},{"key":"2668_CR42","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","volume":"382","author":"AM Gross","year":"2020","unstructured":"Gross, A. M. et al. Selumetinib in children with inoperable plexiform neurofibromas. N. Engl. J. Med. 382, 1430\u20131442 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2668_CR43","doi-asserted-by":"publisher","first-page":"e198890","DOI":"10.1001\/jamanetworkopen.2019.8890","volume":"2","author":"RI Mincu","year":"2019","unstructured":"Mincu, R. I. et al. Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis. JAMA Netw. Open 2, e198890 (2019).","journal-title":"JAMA Netw. Open"},{"key":"2668_CR44","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1093\/annonc\/mdw100","volume":"27","author":"N Stjepanovic","year":"2016","unstructured":"Stjepanovic, N., Velazquez-Martin, J. P. & Bedard, P. L. Ocular toxicities of MEK inhibitors and other targeted therapies. Ann. Oncol. 27, 998\u20131005 (2016).","journal-title":"Ann. Oncol."},{"key":"2668_CR45","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10143-018-0969-6","volume":"43","author":"CA Donofrio","year":"2020","unstructured":"Donofrio, C. A. et al. Pediatric cerebellar pilocytic astrocytoma presenting with spontaneous intratumoral hemorrhage. Neurosurg. Rev. 43, 9\u201316 (2020).","journal-title":"Neurosurg. Rev."},{"key":"2668_CR46","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3171\/2019.12.JNS192155","volume":"134","author":"Y Ishi","year":"2020","unstructured":"Ishi, Y. et al. Association of the FGFR1 mutation with spontaneous hemorrhage in low-grade gliomas in pediatric and young adult patients. J. Neurosurg. 134, 733\u2013741 (2020).","journal-title":"J. Neurosurg."},{"key":"2668_CR47","first-page":"1073","volume":"46","author":"C Matsuura","year":"2018","unstructured":"Matsuura, C. et al. [Diffuse astrocytoma with pilomyxoid features presenting as intratumoral hemorrhage: a case report]. No Shinkei Geka 46, 1073\u20131079 (2018).","journal-title":"No Shinkei Geka"},{"key":"2668_CR48","doi-asserted-by":"publisher","first-page":"249","DOI":"10.4103\/1817-1745.193366","volume":"11","author":"SR Ramdurg","year":"2016","unstructured":"Ramdurg, S. R. & Maitra, J. A rare case of infantile cerebellar pilocytic astrocytoma and thrombocytopenia presenting with intratumoral hemorrhage. J. Pediatr. Neurosci. 11, 249\u2013251 (2016).","journal-title":"J. Pediatr. Neurosci."},{"key":"2668_CR49","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1046\/j.1365-2265.1997.2211032.x","volume":"47","author":"PF Collet-Solberg","year":"1997","unstructured":"Collet-Solberg, P. F. et al. Endocrine outcome in long-term survivors of low-grade hypothalamic\/chiasmatic glioma. Clin. Endocrinol. (Oxf.) 47, 79\u201385 (1997).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"2668_CR50","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S1470-2045(17)30186-9","volume":"18","author":"E Steliarova-Foucher","year":"2017","unstructured":"Steliarova-Foucher, E. et al. International incidence of childhood cancer, 2001\u201310: a population-based registry study. Lancet Oncol. 18, 719\u2013731 (2017).","journal-title":"Lancet Oncol."},{"key":"2668_CR51","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1093\/neuonc\/nos202","volume":"14","author":"AK Gnekow","year":"2012","unstructured":"Gnekow, A. K. et al. Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. Neuro Oncol. 14, 1265\u20131284 (2012).","journal-title":"Neuro Oncol."},{"key":"2668_CR52","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3389\/fped.2018.00079","volume":"6","author":"C Tissot","year":"2018","unstructured":"Tissot, C., Singh, Y. & Sekarski, N. Echocardiographic evaluation of ventricular function\u2014for the neonatologist and pediatric intensivist. Front. Pediatr. 6, 79 (2018).","journal-title":"Front. Pediatr."},{"key":"2668_CR53","doi-asserted-by":"publisher","first-page":"e27682","DOI":"10.1002\/pbc.27682","volume":"66","author":"H Song","year":"2019","unstructured":"Song, H. et al. Cutaneous reactions to targeted therapies in children with CNS tumors: a cross-sectional study. Pediatr. Blood Cancer 66, e27682 (2019).","journal-title":"Pediatr. Blood Cancer"}],"updated-by":[{"DOI":"10.1038\/s41591-025-03709-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000}},{"DOI":"10.1038\/s41591-024-02910-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02668-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02668-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02668-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T03:02:31Z","timestamp":1744858951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02668-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,17]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["2668"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02668-y","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,17]]},"assertion":[{"value":"15 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-024-02910-1","URL":"https:\/\/doi.org\/10.1038\/s41591-024-02910-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-025-03709-4","URL":"https:\/\/doi.org\/10.1038\/s41591-025-03709-4","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.B.K. has received consulting fees from Blueprint Medicine as DSMB Chair and has contracted institutional research with Novartis, Regeneron Pharmaceuticals, Day One Biopharmaceuticals, Spring Works Therapeutics, Bristol Myers Squibb and SonALAsense. L.B.K. also owns stock in Onconova Therapeutics. J.R.H. has received honoraria for consultation from Bayer, Alexion Pharma and Boxer Capital. P.H.D. is on an advisory board with Alexion and is part of the Alexion ICI Sprinkle Study. S.P. is on advisory boards with Bayer, Alexion and Esai and has received research support from Novartis, Bayer and Roche. D.S.Z. has received consulting\/advisory board fees from Bayer, AstraZeneca, Accendatech, Novartis, Day One Biopharmaceuticals, FivePhusion, Amgen, Alexion and Norgine and has received research support from Accendatech. O.W. is on advisory boards with Novartis, Janssen, Roche, Bristol Myers Squibb and AstraZeneca and has received research grants from Day One Biopharmaceuticals, Biomed Valley Discovery, Bristol Myers Squibb, Syndax and PreComb. H.J.K. is on advisory boards with Novartis, Jazz Pharmaceuticals, Takeda, Cartexell and GPCR. D.H. is on advisory boards with Alexion\/AstraZeneca, Bayer, Bristol Myers Squibb, Celgene, Day One Biopharmaceuticals, Janssen, Novartis and Roche and has received research grants from Alexion\/AstraZeneca and Roche. V.L. is on an advisory board with Alexion. C.K. is a study chair of an investigator-sponsored trial for which Day One Biopharmaceuticals provides drug and research support; she also has research relationships with other industry partners. D.S. is on an advisory board with Alexion. L.M., X.Z., A.W., D.D., P.M., I.C. and S.C.B. are employees of Day One Biopharmaceuticals and have received Day One Biopharmaceuticals stock and stock options. K.N. has received advisory board or consulting fees from Y-mAbs, EUSA Pharma, Bayer and Eli Lilly. All remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}